APOLIPOPROTEIN A1 AND APOLIPOPROTEIN B LEVELS, THEIR ASSOCIATIONS WITH ESTIMATED GLOMERULAR FILTRATION RATE AND SELECTED CHARACTERISTICS IN NON-DIALYSIS PATIENTS WITH CHRONIC KIDNEY DISEASE AT HANOI KIDNEY HOSPITAL IN 2026

Trung Dũng Ngô1, , Thị Điệp Ngụy1, Tùng Lĩnh Phan1, Thị Vân Anh Nguyễn1, Thu Trang Trần1, Trường Giang Ngô2, Ngọc Anh Lê3, Thị Hoa Nguyễn4
1 Bệnh viện Thận Hà Nội
2 Học viện Quân y
3 Trường Đại học Y Dược – Đại học Quốc gia Hà Nội
4 Bệnh viện đa khoa Đức Giang

Main Article Content

Abstract

Background: Lipoprotein metabolism abnormalities are common in patients with chronic kidney disease (CKD) and are clinically relevant given the increased cardiovascular risk in this population. Apolipoprotein A1 (Apo A1), apolipoprotein B (Apo B), and the Apo B/Apo A1 ratio may provide additional information on lipoprotein abnormalities beyond conventional lipid parameters. However, data on these parameters and their associations with kidney function in non-dialysis patients with CKD in Vietnam remain limited.


Objectives: To determine the concentrations of apolipoprotein A1, apolipoprotein B, and the Apo B/Apo A1 ratio, and to evaluate their associations with estimated glomerular filtration rate (eGFR) and selected clinical and laboratory characteristics in non-dialysis patients with CKD.


Methods: A cross-sectional study was conducted in 236 participants, including 140 non-dialysis patients with CKD recruited at Hanoi Kidney Hospital and 96 healthy blood donors recruited at Military Central Hospital 108 and Duc Giang General Hospital, from January 1 to August 31, 2026.


Results: Among the 140 non-dialysis patients with CKD, the median Apo A1 and Apo B concentrations were 1.405 g/L and 0.840 g/L, respectively, and the median Apo B/Apo A1 ratio was 0.627; all three measures were significantly higher than those in the control group (p<0.05). Apo A1 was significantly lower in patients with eGFR <60 mL/min/1.73 m² than in those with eGFR ≥60 mL/min/1.73 m² (1.390 vs. 1.510 g/L; p=0.039), whereas no significant differences were observed for Apo B or the Apo B/Apo A1 ratio. No significant correlations were observed between continuous eGFR and Apo A1, Apo B, or the Apo B/Apo A1 ratio. Apo A1 was positively correlated with HDL-C, total cholesterol, and LDL-C; Apo B was positively correlated with total cholesterol, triglycerides, and LDL-C; and the Apo B/Apo A1 ratio was positively correlated with BMI, total cholesterol, triglycerides, and LDL-C and negatively correlated with HDL-C (p<0.05).


Conclusion: Apo A1, Apo B, and the Apo B/Apo A1 ratio were significantly higher in non-dialysis patients with CKD than in healthy individuals. Apo A1 was correlated with several lipid parameters, whereas Apo B and the Apo B/Apo A1 ratio were correlated with several lipid parameters and BMI. However, no significant correlations were observed between continuous eGFR and Apo A1, Apo B, or the Apo B/Apo A1 ratio.

Article Details

References

1. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12(1):7-11. doi:10.1016/j.kisu.2021.11.003
2. Goek ON, Köttgen A, Hoogeveen RC, Ballantyne CM, Coresh J, Astor BC. Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples. Nephrol Dial Transplant. 2012;27(7):2839-2847. doi:10.1093/ndt/gfr795
3. Lecamwasam A, Mansell T, Ekinci EI, Saffery R, Dwyer KM. Blood Plasma Metabolites in Diabetes-Associated Chronic Kidney Disease: A Focus on Lipid Profiles and Cardiovascular Risk. Front Nutr. 2022;9:821209. doi:10.3389/fnut.2022.821209
4. Mehta A, Shapiro MD. Apolipoproteins in vascular biology and atherosclerotic disease. Nat Rev Cardiol. 2022;19(3):168-179. doi:10.1038/s41569-021-00613-5
5. Xu Y, Liu B, Lin L, et al. The association of apolipoprotein B with chronic kidney disease in the Chinese population. Front Endocrinol. 2023;14:1083614. doi:10.3389/fendo.2023.1083614
6. Mazidi M, Webb RJ, Lip GYH, Kengne AP, Banach M, Davies IG. Discordance between LDL-C and Apolipoprotein B Levels and Its Association with Renal Dysfunction: Insights from a Population-Based Study. J Clin Med. 2022;11(2):313. doi:10.3390/jcm11020313
7. Lamprea-Montealegre JA, Sharrett AR, Matsushita K, Selvin E, Szklo M, Astor BC. Chronic kidney disease, lipids and apolipoproteins, and coronary heart disease: The ARIC Study. Atherosclerosis. 2014;234(1):42-46. doi:10.1016/j.atherosclerosis.2014.02.006
8. Dounousi E, Tellis C, Pavlakou P, Duni A, Liakopoulos V, Mark PB, et al. Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients. Oxidative Medicine and Cellular Longevity. 2021:6677012. doi: 10.1155/2021/6677012.
9. Kwon S, Kim DK, Oh KH, et al. Apolipoprotein B is a risk factor for end-stage renal disease. Clin Kidney J. 2020;14(2):617-623. doi:10.1093/ckj/sfz186
10. Welsh C, Celis-Morales CA, Brown R, Mackay DF, Lewsey J, Mark PB, et al. Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease. Circulation. 2019. Aug 13;140(7):542-552. doi: 10.1161/CIRCULATIONAHA.119.041149
11. Sniderman AD, Dufresne L, Pencina KM, Bilgic S, Thanassoulis G, Pencina MJ. Discordance among Apo B, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. Eur heart J. 2024. Jul 12;45(27):2410-2418. doi: 10.1093/eurheartj/ehae258.